FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164880863> ?p ?o ?g. }

• W2164880863 abstract "Abstract Background CTLA-4 (Cytotoxic T lymphocyte antigen-4) is traditionally known as a negative regulator of T cell activation. The blocking of CTLA-4 using human monoclonal antibodies, such as Ipilimumab, is currently used to relieve CTLA-4-mediated inhibition of anti-tumor immune response in metastatic melanoma. Herein, we have analyzed CTLA-4 expression and Ipilimumab reactivity on melanoma cell lines and tumor tissues from cutaneous melanoma patients. Then, we investigated whether Ipilimumab can trigger innate immunity in terms of antibody dependent cellular cytotoxicity (ADCC) or Tumor Necrosis Factor (TNF)-α release. Finally, a xenograft murine model was set up to determine in vivo the effects of Ipilimumab and NK cells on melanoma. Methods CTLA-4 expression and Ipilimumab reactivity were analyzed on 17 melanoma cell lines (14 primary and 3 long-term cell lines) by cytofluorimetry and on 33 melanoma tissues by immunohistochemistry. CTLA-4 transcripts were analyzed by quantitative RT-PCR. Soluble CTLA-4 and TNF-α were tested by ELISA. Peripheral blood mononuclear cells (PBMC), NK and γδT cells were tested in ADCC assay with Ipilimumab and melanoma cell lines . TNF-α release was analyzed in NK-melanoma cell co-cultures in the presence of ipilimumab. In vivo experiments of xenotransplantation were carried out in NOD/SCID mice. Results were analyzed using unpaired Student’s t-test. Results All melanoma cell lines expressed mRNA and cytoplasmic CTLA-4 but surface reactivity with Ipilimumab was quite heterogeneous. Accordingly, about 2/3 of melanoma specimens expressed CTLA-4 at different level of intensity. Ipilimumab triggered, via FcγReceptorIIIA (CD16), ex vivo NK cells as well as PBMC, IL-2 activated NK and γδT cells to ADCC of CTLA-4 + melanoma cells. No ADCC was detected upon interaction with CTLA-4 - FO-1 melanoma cell line. TNF-α was released upon interaction of NK cells with CTLA-4 + melanoma cell lines. Remarkably, Ipilimumab neither affected proliferation and viability nor triggered ADCC of CTLA-4 + T lymphocytes. In a chimeric murine xenograft model, the co-engraftment of Ipilimumab-treated melanoma cells with human allogeneic NK cells delayed and significantly reduced tumor growth, as compared to mice receiving control xenografts. Conclusions Our studies demonstrate that Ipilimumab triggers effector lymphocytes to cytotoxicity and TNF-α release. These findings suggest that Ipilimumab, besides blocking CTLA-4, can directly activate the elimination of CTLA-4 + melanomas." @default.
• W2164880863 created "2016-06-24" @default.
• W2164880863 creator A5016120209 @default.
• W2164880863 creator A5020469162 @default.
• W2164880863 creator A5021075985 @default.
• W2164880863 creator A5025457197 @default.
• W2164880863 creator A5027162539 @default.
• W2164880863 creator A5031396986 @default.
• W2164880863 creator A5036040455 @default.
• W2164880863 creator A5036127131 @default.
• W2164880863 creator A5043415758 @default.
• W2164880863 creator A5043511419 @default.
• W2164880863 creator A5045982942 @default.
• W2164880863 creator A5046614274 @default.
• W2164880863 creator A5054714379 @default.
• W2164880863 creator A5060102558 @default.
• W2164880863 creator A5071929183 @default.
• W2164880863 creator A5073875192 @default.
• W2164880863 creator A5076398704 @default.
• W2164880863 creator A5085307630 @default.
• W2164880863 date "2013-05-01" @default.
• W2164880863 modified "2023-09-30" @default.
• W2164880863 title "The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production" @default.
• W2164880863 cites W1536480181 @default.
• W2164880863 cites W1542616270 @default.
• W2164880863 cites W1966185020 @default.
• W2164880863 cites W1982889687 @default.
• W2164880863 cites W1985905844 @default.
• W2164880863 cites W1993851289 @default.
• W2164880863 cites W2007747583 @default.
• W2164880863 cites W2008062915 @default.
• W2164880863 cites W2011770999 @default.
• W2164880863 cites W2012972418 @default.
• W2164880863 cites W2013043293 @default.
• W2164880863 cites W2023821657 @default.
• W2164880863 cites W2026767467 @default.
• W2164880863 cites W2033805603 @default.
• W2164880863 cites W2035740887 @default.
• W2164880863 cites W2037920661 @default.
• W2164880863 cites W2049784279 @default.
• W2164880863 cites W2052339438 @default.
• W2164880863 cites W2067492921 @default.
• W2164880863 cites W2079220522 @default.
• W2164880863 cites W2091250703 @default.
• W2164880863 cites W2094366129 @default.
• W2164880863 cites W2095046039 @default.
• W2164880863 cites W2097995306 @default.
• W2164880863 cites W2101822729 @default.
• W2164880863 cites W2104925898 @default.
• W2164880863 cites W2113805798 @default.
• W2164880863 cites W2125474740 @default.
• W2164880863 cites W2131633419 @default.
• W2164880863 cites W2146934919 @default.
• W2164880863 cites W2148245227 @default.
• W2164880863 cites W2149244682 @default.
• W2164880863 cites W2161240454 @default.
• W2164880863 cites W2162466652 @default.
• W2164880863 cites W2162540156 @default.
• W2164880863 cites W2166980833 @default.
• W2164880863 cites W2167902402 @default.
• W2164880863 doi "https://doi.org/10.1186/1479-5876-11-108" @default.
• W2164880863 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3663700" @default.
• W2164880863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23634660" @default.
• W2164880863 hasPublicationYear "2013" @default.
• W2164880863 type Work @default.
• W2164880863 sameAs 2164880863 @default.
• W2164880863 citedByCount "127" @default.
• W2164880863 countsByYear W21648808632013 @default.
• W2164880863 countsByYear W21648808632014 @default.
• W2164880863 countsByYear W21648808632015 @default.
• W2164880863 countsByYear W21648808632016 @default.
• W2164880863 countsByYear W21648808632017 @default.
• W2164880863 countsByYear W21648808632018 @default.
• W2164880863 countsByYear W21648808632019 @default.
• W2164880863 countsByYear W21648808632020 @default.
• W2164880863 countsByYear W21648808632021 @default.
• W2164880863 countsByYear W21648808632022 @default.
• W2164880863 countsByYear W21648808632023 @default.
• W2164880863 crossrefType "journal-article" @default.
• W2164880863 hasAuthorship W2164880863A5016120209 @default.
• W2164880863 hasAuthorship W2164880863A5020469162 @default.
• W2164880863 hasAuthorship W2164880863A5021075985 @default.
• W2164880863 hasAuthorship W2164880863A5025457197 @default.
• W2164880863 hasAuthorship W2164880863A5027162539 @default.
• W2164880863 hasAuthorship W2164880863A5031396986 @default.
• W2164880863 hasAuthorship W2164880863A5036040455 @default.
• W2164880863 hasAuthorship W2164880863A5036127131 @default.
• W2164880863 hasAuthorship W2164880863A5043415758 @default.
• W2164880863 hasAuthorship W2164880863A5043511419 @default.
• W2164880863 hasAuthorship W2164880863A5045982942 @default.
• W2164880863 hasAuthorship W2164880863A5046614274 @default.
• W2164880863 hasAuthorship W2164880863A5054714379 @default.
• W2164880863 hasAuthorship W2164880863A5060102558 @default.
• W2164880863 hasAuthorship W2164880863A5071929183 @default.
• W2164880863 hasAuthorship W2164880863A5073875192 @default.
• W2164880863 hasAuthorship W2164880863A5076398704 @default.
• W2164880863 hasAuthorship W2164880863A5085307630 @default.
• W2164880863 hasBestOaLocation W21648808631 @default.
• W2164880863 hasConcept C109316439 @default.
• W2164880863 hasConcept C137061746 @default.

• next